Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based biopharmaceutical company Antisense Pharma has secured EUR8m from MIG Funds 2, 3 and 9 as well as GAF to increase the international pharmaceutical and capital market experience of the company management
Subscribe to our email newsletter
Further, Karl-Hermann Schlingensiepen, the current CEO of the company, has changed from the operative management of Antisense Pharma to a strategic consulting function.
He will concentrate on consulting on the areas of preclinical research, patents, regulatory affairs and representation at international congresses as of 1 July 2011.
The company has named Hubert Heinrichs as the acting CEO of the company.
Furthermore, the company has started preparation for a second international clinical trial of pivotal Phase II/III study on pancreatic cancer.
MIG Verwaltungs chief executive Michael Motschmann said with this major entry into the systemic, intravenous application in solid tumors, they share Antisense Pharma’s hope that trabedersen could become the first medication approved for second-line therapy of pancreatic cancer.
"Trabedersen could give new hope to patients suffering from this extremely aggressive type of cancer and open up a greatly needed but thus far completely vacant market niche along with its corresponding high revenue potential," Motschmann said.
"At the same time, this means a risk reduction for the development of trabedersen, as this medication now has several marketing opportunities if the trials are successful."